Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy
Histone deacetylase (HDAC) inhibitors have emerged as a new class of antitumor agent for various types of tumors. MPT0B291, a novel selective inhibitor of HDAC6, demonstrated significant antiproliferative activity in various human cancer cell types. However, MPT0B291 has very low water solubility, w...
Main Authors: | Athika Darumas Putri, Pai-Shan Chen, Yu-Lin Su, Jia-Pei Lin, Jing-Ping Liou, Chien-Ming Hsieh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/10/1728 |
Similar Items
-
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
by: Masumeh Sanaei, et al.
Published: (2019-01-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
Advanced Progress of Histone Deacetylases in Rheumatic Diseases
by: Liu XM, et al.
Published: (2024-02-01) -
Role of histone deacetylase inhibitors in non-neoplastic diseases
by: Chunxiao Zhou, et al.
Published: (2024-07-01) -
Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
by: Svetlana Demyanenko, et al.
Published: (2021-10-01)